LHFPL4: A Potential Drug Target and Biomarker (G375323)

Target Name: LHFPL4

NCBI ID: G375323

LHFPL4

LHFPL4: A Potential Drug Target and Biomarker

LHFPL4 (GARLH4) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and structure make it an attractive target for researchers to investigate and develop new treatments.

The gene LHFPL4, which stands for long hairpin-like protein 4, was first identified in 2012 by researchers at the University of California, San Diego. It is a protein that is expressed in various tissues and cells in the body, including the brain, heart, and immune system.

One of the key features of LHFPL4 is its unique structure. It is a long protein that has a hairpin-like loop at its C-terminus. This loop is thought to play a critical role in the protein's function and stability. Studies have shown that LHFPL4 has a high degree of homogeneity, meaning that it has the same sequence throughout its length. This is unusual for a protein, as most proteins have a great deal of variation in their sequence.

Another interesting feature of LHFPL4 is its expression pattern. It is expressed in many different tissues and cells in the body, including the brain, but it is not as well-known as other proteins. This makes it an attractive target for researchers because it is less likely to have adverse effects in humans.

In addition to its unique structure and expression pattern, LHFPL4 has also been shown to play a role in several diseases. One of the most promising areas of research is the potential for LHFPL4 to be used as a drug target.

There is a growing body of evidence to suggest that LHFPL4 may be involved in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that LHFPL4 is involved in the development and progression of these diseases.

For example, studies have shown that LHFPL4 is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a wide range of symptoms, including memory loss, difficulty with movement, and changes in mood and personality.

In addition to its involvement in neurodegenerative diseases, LHFPL4 has also been shown to be involved in the development of certain cancers. For example, studies have shown that LHFPL4 is often expressed in breast cancer cells, and that it may play a role in the growth and survival of these cells.

Another promising area of research is the potential for LHFPL4 to be used as an biomarker for cancer. Many cancer treatments are designed to target specific proteins, and researchers may be able to use LHFPL4 as a biomarker to track the effectiveness of these treatments.

In addition to its potential as a drug target and biomarker, LHFPL4 is also of interest to researchers because of its unique structure and expression pattern. These features make it an attractive target for researchers who are looking for new and innovative treatments for a wide range of diseases.

Overall, LHFPL4 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its unique structure and expression pattern make it an attractive target for researchers who are looking to investigate its role in the development and progression of these diseases. Further research is needed to fully understand the function and potential of LHFPL4.

Protein Name: LHFPL Tetraspan Subfamily Member 4

Functions: Plays a role in the regulation of inhibitory synapse formation and function by being involved in maintening gamma-aminobutyric acid receptors (GABAARs) clustering and their associated scaffold proteins at inhibitory synaptic sites. Acts in concert with NLGN2 to recruit or stabilize GABAARs

The "LHFPL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LHFPL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets